OS Therapies Reports Strong Survival Data for Bone Cancer Treatment
OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.
Stocks · News reference
OS Therapies Announces Statistically Significant Benefit For OST-HER2-Treated Patients In An Interim 3-Year Overall Survival Data Analysis
Overall survival data when compared with a combined published historical control arm being used for regulatory interactions. The analysis is from the Company's Phase 2b trial for the prevention or delay of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — OS Therapies Inc (OSTX)
Filed: 2026-08-21 AccNo: 0001213900-26-092651 Size: 603 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
OS Therapies Enters Open Market Sale Agreement With Jefferies; May Offer Common Stock Up To $75M Through Jefferies
-SEC Filing